Bohai Pharmaceuticals to Host Fiscal Q1 2011 Earnings Conference Call on November 15th at 11:00 a.m. Eastern Management Team to Discuss Bohai's Lead Products, Business Strategy and Recent Financial Performance in Fiscal 2011

YANTAI, China, Nov 12, 2010 (BUSINESS WIRE) -- Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, will host a conference call on Monday, November 15, 2010, at 11:00 a.m. Eastern to discuss the financial results for its fiscal first quarter ended September 30, 2010. Bohai's 10-Q and corresponding earnings release is expected to be filed prior to the call.

In addition to Bohai's financial performance for the quarter, management will also discuss China's expanding Traditional Chinese Medicine market, including new PRC mandated polices and reimbursement initiatives that support the use of TCM.

"Bohai held its first earnings conference call as a U.S.-listed company several weeks ago, reporting record levels of revenue and earnings in fiscal 2010," said Mr. Hongwei Qu, Chairman, President and CEO of Bohai Pharmaceuticals. "As we approach the announcement of earnings for the fiscal first quarter, we look forward to sharing news of our financial results and proactive growth initiatives for 2011 and beyond with our investors." The teleconference can be accessed by dialing 877-407-8031 when calling within the United States or 201-689-8031 when calling internationally. Please dial in 10 minutes prior to the beginning of the call. There will be a playback available until December 16, 2010. To listen to the playback dial 877-660-6853 when calling within the United States, or 201-612-7415 when calling internationally and use account number: 286, in conjunction with replay ID number: 361002.

The conference call will be simultaneously webcast and available on the company's website,, under the "Events and Presentations" tab of the "Investors" section.

About Bohai Pharmaceuticals Group, Inc.

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH) is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on Traditional Chinese Medicine in China. Bohai's medicines address common health problems such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. Bohai's products are sold either by prescription through hospitals or over-the-counter through local pharmacies and retail drug store chains. Bohai has approximately 600 employees, including approximately 300 sales representatives, operating from 20 offices throughout China. Bohai's three lead products, Tongbi Capsules, Tongbi Tablets and Lung Nourishing Cream, are eligible for reimbursement under China's National Medical Insurance Program.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Investor Relations Portal, Investor Fact Sheet and Overview Video.

For additional information, please visit Bohai's corporate website:

Additional Information Relating to Bohai's Trading Data Due to certain recent disruptions in the marketplace relating to quotations on the OTC Bulletin Board operated by FINRA (OTCBB), incomplete trading data may exist for certain companies like Bohai. Real-time trading data for Bohai on the OTCQB market is available through the below link. Readers are advised that OTCQB market is operated by the owner of, and Bohai Pharmaceuticals Group, Inc. makes no representation or warranty regarding the OTCQB market.

For real-time trading data for Bohai on the OTCQB market, including Level 2 quotes, please visit:

Cautionary Note Regarding Forward Looking Statements This press release, the conference call referred to herein and the statements of representatives of Bohai Pharmaceuticals Group, Inc. (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the Securities and Exchange Commission ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.

SOURCE: Bohai Pharmaceuticals Group, Inc.

CONTACT: Company Contact: Bohai Pharmaceuticals Group, Inc. Gene Hsiao, Chief Financial Officer 212-521-4470 or Financial Communications Contact: Trilogy Capital Partners - Asia Darren Minton, President Toll-free: 800-592-6067 Copyright Business Wire 2010 -0- KEYWORD: China

Asia Pacific INDUSTRY KEYWORD: Health

Alternative Medicine

Pharmaceutical SUBJECT CODE: Advisory


Conference Call